Clinical effects of everolimus in the subjects with autism spectrum disprders (ASD) in relation to tuberous sclerosis.

Clinical effects of everolimus in the ubjects with tuberous sclerosis. - Clinical effects of everolimus in the subjects with ASD

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1090220258

Enrollment

Registered

2016-08-02

Start date

2015-06-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

there are a few individuals with TSC with SEGA who exhibite ASD symptoms.

Interventions

Intervention type: Name of intervention: Dose form / Japanese Medical Device Nomenclature:POWDER Route of administration / Site of application:ORAL Dose per administration:3.5mg 3.5mg/M2 mg/M2 Dosing

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Individuals with autism spectrum disorders in TSC

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Aberrant Behavior Checklist (ABC), Social Resposiveness Scale (SRS), Social communication Questionnaire (SCQ)	—

Secondary

Measure	Time frame
Aberrant Behavior Checklist (ABC), Social Resposiveness Scale (SRS)	—

Countries

Japan

Contacts

Public ContactKunio Yui

Dokkyo Medical University, School of Medicine

yui16@bell.ocn.ne.jp+81-282-86-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026